Glioblastoma Clinical Trials in Philadelphia, PA

Glioblastoma Clinical Trials in Philadelphia, PA

View the best 10 glioblastoma medical studies in Philadelphia, Pennsylvania. Access promising new therapies by applying to a Philadelphia-based Glioblastoma clinical trial.

Trials in Philadelphia, Pennsylvania

Here are the top 10 medical studies for glioblastoma in Philadelphia, Pennsylvania

Image of NCT02285959 in Philadelphia, United States.

Bevacizumab

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial is testing a new way to give chemotherapy to people with a certain type of brain tumor. The hope is that it will help them live longer.
Image of Children's Oncology Group in Philadelphia, United States.

Selinexor +1 More

Selective Inhibitors of Nuclear Export

Recruiting1 awardPhase 1 & 2
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
Image of Investigation Site in Newark, United States.

IGV-001 +2 More

Cell Immunotherapy

Recruiting0 awardsPhase 2
This trial will compare a new treatment for glioblastoma to placebo to see if it extends survival.
Image of Children's Hospital Colorado in Aurora, United States.

Ribociclib +1 More

CDK4/6 Inhibitor

Recruiting1 awardPhase 2
This trial is testing whether the combination of ribociclib and everolimus can help children and young adults with aggressive brain tumors live longer. Everolimus is a medication that has been approved for treating various cancers. These drugs are taken by mouth and work by stopping cancer cells from growing. The study focuses on patients whose tumors have specific genetic changes that make them hard to treat with standard therapies.
Image of Barrow Neurological Institute in Phoenix, United States.

Berubicin +1 More

Anthracenedione

Recruiting1 awardPhase 2
This trial will compare the effect of two cancer drugs, berubicin and lomustine, on overall survival in patients with glioblastoma multiforme (GBM) who have failed standard first line therapy. A futility analysis will be performed after approximately 30-50% of planned patients have completed the primary endpoint at 6 months.
Image of Brigham and Women's Hospital in Boston, United States.

Cemiplimab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial is testing the safety and effectiveness of combining two drugs, ASP8374 and cemiplimab, for people with recurrent brain cancer. The study aims to find the best dose and see if the combination helps before surgery. The drugs work by boosting the immune system to fight cancer cells. Cemiplimab has been previously tested in combination with other treatments for severe cancers.
Image of Rady Children's Hospital in San Diego, United States.

Fimepinostat

Histone Deacetylase (HDAC) Inhibitor

Recruiting1 awardPhase < 1
This trial is testing how well fimepinostat works in treating patients with newly diagnosed brain tumors. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Image of University of Kansas Medical Center in Olathe, United States.

TVI-Brain-1 +2 More

CAR T-cell Therapy

Recruiting1 awardPhase 2 & 3
This trial will study an immunotherapy combining a cancer-patient's own cells and standard treatment to fight glioblastoma. Immune cells will be harvested from the patient, stimulated and expanded, then infused back.
Image of Children's Hospital of Alabama in Birmingham, United States.

Ivosidenib

IDH1 Inhibitor

Recruiting1 awardPhase 2
This trial will test ivosidenib to see if it can help patients with advanced solid tumors, lymphoma, or histiocytic disorders that have IDH1 mutations.
Image of University of Alabama at Birmingham Cancer Center in Birmingham, United States.

Ipilimumab +2 More

Checkpoint Inhibitor

Recruiting1 awardPhase 2 & 3
This trial is testing whether adding immunotherapy to radiation therapy can help people with newly diagnosed glioblastoma that has an unmethylated MGMT.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.